Provided by Tiger Fintech (Singapore) Pte. Ltd.

VistaGen Therapeutics

2.38
+0.01500.64%
Post-market: 2.37-0.0050-0.21%17:10 EDT
Volume:112.39K
Turnover:270.47K
Market Cap:68.55M
PE:-1.54
High:2.45
Open:2.38
Low:2.35
Close:2.36
Loading ...

Vistagen Therapeutics Inc - Ph284 Demonstrates No Serious Adverse Events

THOMSON REUTERS
·
14 Jan

BRIEF-Vistagen Initiates Fasedienol Repeat Dose Study For The Acute Treatment Of Social Anxiety Disorder

Reuters
·
10 Jan

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
10 Jan

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Business Wire
·
10 Jan

VistaGen Therapeutics Advances Neurocircuitry Treatments

TIPRANKS
·
07 Dec 2024

Stifel Nicolaus Sticks to Their Buy Rating for VistaGen Therapeutics (VTGN)

TIPRANKS
·
21 Nov 2024

VistaGen Therapeutics’ Promising Clinical Progress and Strong Financial Position Justify Buy Rating

TIPRANKS
·
09 Nov 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ...

GuruFocus.com
·
08 Nov 2024

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

Zacks
·
08 Nov 2024

VistaGen Therapeutics Q2 2025 GAAP EPS $(0.42) Misses $(0.39) Estimate, Sales $183.000K Miss $223.333K Estimate

Benzinga
·
08 Nov 2024

Vistagen Therapeutics Inc - Qtrly Shr Loss $0.42

THOMSON REUTERS
·
08 Nov 2024

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

THOMSON REUTERS
·
08 Nov 2024

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Business Wire
·
08 Nov 2024

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Business Wire
·
05 Nov 2024

Press Release: Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Dow Jones
·
01 Nov 2024